1 Baseline Predictors for One Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration Ying G-S, Maguire MG.

Slides:

Advertisements

Similar presentations

Retinal Vein Occlusion 2010 An Evidence-Based Approach Corticosteroids, Implants, and Anti VEGF Therapies Allen C. Ho, MD Professor of Ophthalmology Wills.

Advertisements

The Diabetic Retinopathy Clinical Research Network

The Diabetic Retinopathy Clinical Research Network Effects of Intravitreal Ranibizumab or Triamcinolone on Diabetic Retinopathy Jennifer K. Sun, MD, MPH.

OCT OF MCULAR DISEASES DEHGHANI.A near infrared light near infrared light cross-sectional images of tissue cross-sectional images of tissue High resolution)

PURPOSE: Ranibizumab (Lucentis®) is a humanized monoclonal antibody Fab fragment, specifically designed for ocular use. It selectively binds to and inhibits.

IMAGING in AMD From Fluorescein Angiography To the Spectral Domain OCT

Grand Rounds Best Disease Mark Sherman MD University of Louisville Department of Ophthalmology and Visual Sciences 04/04/2014.

The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.

Driving and Age-related Macular Degeneration (AMD) Rogan Fraser Macular Research Unit Centre for Eye Research Australia.

AMD management: what changes with a new player?

Elvin H. Yildiz, Elisabeth J. Cohen, Ajoy S. Virdi, Kristin M. Hammersmith, Peter R Laibson, and Christopher J. Rapuano Cornea Service, Wills Eye Institute,

Diabetic Retinopathy Clinical Research Network

Everyone’s Vision Can Change With Age  Some vision changes make it difficult to perform everyday activities.  These changes can also impact one’s feeling.

ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.

The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.

Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema Sponsored by the National Eye Institute,

Beginning of the chapter Macular degeneration and Genetics (AMD Sensor) 32.

1 Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Jaffe GJ, Martin DF, Toth CA, Daniel.

C.A. Curcio, , ALARMGS Tutorial Clinico-pathologic Correlation: The Alabama Age-Related Maculopathy Grading System (ALARMGS) Christine A.Curcio,

European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated.

Mahmood J Showail 11/03/2009. A 17 -year-old high school female student presented to our clinic with history of sudden decrease of vision in her left.

The Diabetic Retinopathy Clinical Research Network

© 2012 Direct One Communications, Inc. All rights reserved. 1 Treatment of Exudative AMD: Data from the CATT and IVAN Trials Matthew T. Witmer, MD Weill.

Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):

Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 3 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education.

1 Pharmacogenetics for Genes Associated with Age-Related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) Hagstrom SA, Ying G-S,

TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia Dr.Muhammad Hamza North Devon District NHS Hospital NICE.

Retinal nerve fiber layer thickness change in patients with wet AMD treated with ranibizumab, short term results Advantages: To determine the effect of.

Gene Transfer for Neovascular Age- Related Macular Degeneration Peter A. Campochiaro The Wilmer Eye Institute The Johns Hopkins University School of Medicine.

Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 4 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: VEGFA and VEGFR1 and Response to Anti-VEGF Hagstrom SA, Ying G, Pauer GJT, et.

Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,

The Diabetic Retinopathy Clinical Research Network Green or Yellow Laser for Diabetic Macular Edema Sponsored by the National Eye Institute, National Institutes.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: AMD in the Age-Related Eye Disease Study Chew EY, Clemons TE, Agrón E, et al;

1 Slides Shown at FDA Advisory Committee Eyetech Pharmaceuticals Pfizer, Inc. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting 27 August 2004.

1 Incidence of CNV in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Maguire MG, Daniel E, Shah AR, Grunwald.

Sponsored by the National Eye Institute,

Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health.

OPHTHALMOLOGY MACULA DEGENERATION MBChB 4 Prof P Roux 2012.

COMPARATIVE EFFICACY OF INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR OEDEMA J.A. Montero, J.M. Ruiz-Moreno VISSUM, Alicante.

Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Single-Nucleotide Polymorphisms and Age-Related Macular Degeneration Maguire MG,

CATT objectives To determine whether off-lable “Avastin” works as well as approved medication for neovascular AMD- “Lucentis” To evaluate how often treatment.

Diabetic Retinopathy Clinical Research Network

CERA Age-related macular degeneration- (AMD) information forum

Retina Imaging Conference Denis Jusufbegovic, M.D. University of Louisville Department of Ophthalmology and Visual Sciences 2/11/16.

The Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year.

Secondary Analysis of Clinical Trials Data – A Biostatistician’s Experience Gui-shuang Ying, PhD Center for Preventive Ophthalmology and Biostatistics.

Volume 124, Issue 2, Pages (February 2017)

A 73 years old male decrese of his VA(OD)

가톨릭대학교 의과대학 안과 및 시과학 교실 R3 장동진 / Pf.이원기

Volume 122, Issue 3, Pages (March 2015)

Copyright © 2005 American Medical Association. All rights reserved.

Retina Centre of Ottawa Clinical Trials

AGE-RELATED MACULAR DEGENERATION (AMD)

JAMA Ophthalmology Journal Club Slides: Validity of the Age-Related Eye Disease Study Grading Scale Vitale S, Clemons TE, Agrón E, et al; Age-Related Eye.

Choroidal Neovascular

Geographic Atrophy in a Clinical Trial Environment

Do CNV Subtypes Matter for Prognosis, Diagnosis, and Treatment?

A presentation to: Meeting name Date

A 73 years old male decrese of his VA(OD)

AMD update Macular research.

Wet AMD trials Hibba Soomro.

Should We Dry the Retina Faster for Longer

A presentation to: Meeting name Date

Diabetic Retinopathy Clinical Research Network

Colin Tan, Alex Tham, Tiakumzuk Sangtam, Kah-Guan Au Eong

Diabetic Retinopathy Clinical Research Network

Presentation transcript:

1 Baseline Predictors for One Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration Ying G-S, Maguire MG Ying G-S, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF for the CATT Research Group Available through Ying G-S, Maguire MG Ying G-S, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF for the CATT Research Group Available through Supported by Cooperative Agreements from the National Eye Institute, National Institutes of Health, DHHS

Age Mean VA (SE)Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline VA in Study Eye Mean VA (SE) Mean VA Change (SE) % of ≥3-lines Gain 20/X Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline VA in Fellow Eye % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline IOP Mean VA Change (SE) Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline CNV Area Mean VA (SE) Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Lesion Type Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

RAP Lesion Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline Geographic Atrophy Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline Foveal Thickness Mean VA (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Baseline RPE Elevation Mean VA (SE) Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Conclusions Early treatment before VA is profoundly affected will achieve the best VA outcomes 12 Baseline VAVA at 1 YearChange in VA at 1 Year Mean (SE) P-valueMean(SE) P-value < < / / (0.8)3.3 (0.7) 20/ / (0.7)8.4 (0.7) 20/100 – 20/ (1.0)12.0 (1.0) 20/ / (1.8)7.6 (1.7) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:

Conclusions

Conclusions Baseline predictors of one year VA outcomes are: Baseline predictors of one year VA outcomes are: Baseline PredictorVA scoreVA Change≥3-lines gain Older Age ↓↓U Worse VA - study eye ↓↑↑ Larger CNV Area ↓↓↓ RPE elevation ↓↓↓ Abnormal IOP ↓↓ > Foveal thickness Inverted U Thin ↓ RAP lesion ↑↑ Any classic ↓ GA ↓ Worse VA - fellow eye ↓ Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120: